Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential
NEW YORK and SANTA BARBARA, Calif., July 30, 2024 – Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck. The updated presentation provides an in-depth look at the company’s strategic vision, scientific advancements, and growth […]
Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines
NEW YORK and SANTA BARBARA, CA, July 22, 2024 — Phytanix Bio, an innovative pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, and Chain Bridge I (Nasdaq: CBRG) (“CBRG”), a special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, today announced […]